See more : UBI Blockchain Internet, Ltd. (UBIA) Income Statement Analysis – Financial Results
Complete financial analysis of Cronos Group Inc. (CRON) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cronos Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- BCE Inc. (BCE-PY.TO) Income Statement Analysis – Financial Results
- Harris Exploration, Inc. (HXPN) Income Statement Analysis – Financial Results
- ISM Resources Corp. (ISMRF) Income Statement Analysis – Financial Results
- Brazil Potash Corp. (GRO) Income Statement Analysis – Financial Results
- Lemtech Holdings Co., Limited (4912.TW) Income Statement Analysis – Financial Results
Cronos Group Inc. (CRON)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.thecronosgroup.com
About Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 87.24M | 91.90M | 74.44M | 46.72M | 23.75M | 11.53M | 3.25M | 412.32K | 0.00 | 0.00 | -195.61K |
| Cost of Revenue | 75.33M | 79.94M | 91.97M | 72.55M | 41.61M | 3.26M | 1.98M | 1.44M | 144.98K | 32.16K | 0.00 |
| Gross Profit | 11.91M | 11.97M | -17.53M | -25.83M | -17.86M | 8.27M | 1.27M | -1.03M | -144.98K | -32.16K | -195.61K |
| Gross Profit Ratio | 13.65% | 13.02% | -23.56% | -55.29% | -75.22% | 71.76% | 39.08% | -249.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 5.84M | 13.38M | 23.33M | 20.37M | 12.16M | 1.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 58.23M | 86.29M | 106.63M | 95.89M | 60.99M | 15.90M | 7.00M | 2.78M | 1.47M | 2.02M | 0.00 |
| Selling & Marketing | 22.70M | 22.28M | 44.94M | 34.39M | 23.05M | 3.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 80.93M | 108.58M | 151.57M | 130.28M | 84.04M | 18.92M | 7.00M | 2.78M | 1.47M | 2.02M | 423.86K |
| Other Expenses | 9.93M | 6.03M | 4.48M | 2.87M | 2.10M | 922.15K | 430.22K | 284.76K | 81.66K | 207.54K | 0.00 |
| Operating Expenses | 96.71M | 127.98M | 179.39M | 153.51M | 98.29M | 21.57M | 7.43M | 3.07M | 1.55M | 2.22M | 423.86K |
| Cost & Expenses | 172.04M | 207.92M | 271.35M | 226.07M | 139.91M | 24.82M | 4.92M | 2.00M | 1.69M | 2.26M | 423.86K |
| Interest Income | 51.24M | 22.54M | 9.07M | 18.60M | 28.62M | 0.00 | 3.20K | 4.92K | 29.97K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 22.54M | 27.00K | 186.00K | 27.98M | 78.56K | 100.20K | 177.27K | 325.17K | 0.00 | 0.00 |
| Depreciation & Amortization | 8.26M | 13.12M | 15.40M | 7.05M | 3.91M | 1.84M | 792.05K | 284.76K | 81.66K | 28.11K | 0.00 |
| EBITDA | -72.15M | -91.27M | -192.28M | -70.40M | -1.41B | -18.85M | -5.35M | -1.17M | 559.96K | -3.25M | -619.48K |
| EBITDA Ratio | -82.70% | -64.40% | 29.81% | -342.66% | -5,917.22% | -100.74% | -23.20% | -284.94% | 0.00% | 0.00% | 316.69% |
| Operating Income | -84.80M | -116.01M | 6.79M | -179.35M | -121.48M | -13.29M | -1.68M | -1.23M | 540.34K | -3.08M | -619.48K |
| Operating Income Ratio | -97.20% | -126.23% | 9.12% | -383.88% | -511.51% | -115.32% | -51.64% | -297.13% | 0.00% | 0.00% | 316.69% |
| Total Other Income/Expenses | 11.13M | -18.55M | 129.46M | 1.35M | 1.29B | -478.00K | 3.78M | -82.85K | -344.79K | -1.11M | 0.00 |
| Income Before Tax | -73.67M | -134.56M | -397.14M | -73.27M | 1.17B | -13.74M | 2.22M | -1.31M | 155.05K | -4.15M | -619.48K |
| Income Before Tax Ratio | -84.44% | -146.41% | -533.53% | -156.84% | 4,907.68% | -119.19% | 68.32% | -317.23% | 0.00% | 0.00% | 316.69% |
| Income Tax Expense | -3.23M | 34.18M | -431.00K | 1.35M | -1.29B | 359.02K | 236.98K | -422.59K | -123.23K | 2.99M | 0.00 |
| Net Income | -73.96M | -168.73M | -396.70M | -74.62M | 2.46B | -13.93M | 1.98M | -885.40K | 278.28K | -4.15M | -619.48K |
| Net Income Ratio | -84.78% | -183.60% | -532.95% | -159.72% | 10,338.43% | -120.80% | 61.02% | -214.74% | 0.00% | 0.00% | 316.69% |
| EPS | -0.19 | -0.45 | -1.07 | -0.21 | 7.92 | -0.08 | -0.01 | -0.01 | 0.01 | -0.13 | -0.05 |
| EPS Diluted | -0.19 | -0.45 | -1.07 | -0.21 | 7.16 | -0.08 | -0.01 | -0.01 | 0.01 | -0.13 | -0.05 |
| Weighted Avg Shares Out | 380.96M | 376.96M | 370.39M | 351.58M | 310.07M | 172.27M | 134.80M | 78.25M | 36.41M | 31.95M | 12.75M |
| Weighted Avg Shares Out (Dil) | 380.96M | 376.96M | 370.39M | 351.58M | 342.81M | 172.27M | 176.79M | 78.25M | 43.69M | 32.24M | 12.75M |
Cronos Group Inc. to Speak at Bernstein's 40th Annual Strategic Decisions Conference
TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein's 40th Annual Strategic Decisions Conference...
Cronos Terminates Sale-Leaseback of Peace Naturals Campus
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it has terminated its agreement (the “Sale Agreement”) with Future Farmco Canada Inc. (the “Buyer”), for the sale and...
Schedule III Windfall: 3 Stocks to Buy BEORE the Cannabis Reclassification
I have talked about cannabis stocks to buy in several instances in the last few quarters. However, the timing for exposure couldn't be better than now for several reasons.
3 Penny Stocks That Could Be Millionaire-Makers: May Edition
Investors largely look at penny stocks to buy from a trading or speculation perspective. The idea is to sell when the stock doubles or triples.
Laugh Your Way to the Bank: 3 Meme Stocks to Buy as the Mania Returns
The meme stock rally of 2021 will go down in the books of financial history as one of the craziest periods of euphoria. The big meme stock rally was followed by an extended period of correction for speculative stocks.
7 Growth Stocks to Buy Now for 20X Returns by 2030
The single biggest quality of an investor that can make him/her a millionaire is patience. With some research, it's not difficult to spot quality growth stocks to buy.
7 Penny Stocks to Buy for 100% Returns on Potential Policy Shifts
When policymakers pursue rate cuts, the main idea is to lower the cost of money for businesses and consumers. This translates into higher investment and consumption spending and GDP growth accelerates.
Cannabis Stocks CGC, TLRY, ACB, MSOS, CRON Pop as Justice Department Moves on Rescheduling
Cannabis stocks are once again on the move today, with some big names being seen across the sector. Shares of Canopy Growth (NASDAQ: CGC ), Tilray (NASDAQ: TLRY ), Aurora Cannabis (NASDAQ: ACB ), AdvisorShares Pure US Cannabis ETF (NYSEARCA:...
Card payments remain a ‘challenge' for legal cannabis as major banks avoid the sector. Changing classification won't help.
When Ellis Soodak was planning the launch of Verdi Cannabis dispensary in New York City, he didn't want to face the dangers his father did at the family's liquor store in the 1970s and 80s.
This Is How Marijuana Stocks Will Be Impacted By Reform In 2024
As the cannabis industry continues its growth in 2024, a confluence of regulatory, demographic, and market trends is shaping the sector. This has presented a fertile ground for savvy investors. Here's a deeper look into the evolving landscape of cannabis...
Source: https://incomestatements.info
Category: Stock Reports